SEC For	m 4																	
FORM 4			UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section obligat	this box if no lo n 16. Form 4 or ions may contin tion 1(b).		STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
	nd Address of MEYER			2. Issuer Name and Ticker or Trading Symbol Oncternal Therapeutics, Inc. [ONCT]							eck all applica	able)	,		wner			
(Last) 12230 E	(F L CAMINC	(Middle) 230		3. Date of Earliest Transaction (Month/Day/Year) 02/21/2023							X Officer (give title Other (specify below) below) Chief Executive Officer							
(Street) SAN DIEGO CA			92130	4.	Line) X Fo) <mark>X</mark> Form fil	or Joint/Group Filing (Check Applicable rm filed by One Reporting Person rm filed by More than One Reporting					
(City)	(S	state)	(Zip)	riveti		ouritio		auirod D	ionoood	of or Do	noficially							
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Trans Date (Month/l)				ansactio			e, 3. Transacti Code (Ins	on Dispose	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4		5. Amount of		Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Table II - Deri (e.g.					uired, Dis s, options,				Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)					
Stock Option	\$0.96	02/21/2023		A		650,000		(1)	02/21/2033	Common Stock	650,000	\$0.00	650,0	650,000				
Stock Option	\$0.96	02/21/2023		A		65,000		(1)	02/21/2023	Common Stock	65,000	\$0.00	65,00	00	I	By Spouse		

Explanation of Responses:

\$0.81

1. 25% of the shares subject to the stock option vest on first anniversary of the date of grant, and the remaining shares subject to the option vest in 36 equal monthly installments, subject to the recipient's continued employment or service with the Issuer on each such date.

(2)

2. On November 14, 2018, the recipient received a stock option to purchase 168,787 shares, which vest on the achievement of certain pre-established strategic milestones. The issuer's Compensation Committee determined that two such strategic milestones were achieved, resulting in the vesting of 42,196 shares subject to the stock option effective February 21, 2023. 21,098 shares subject to the option remain unvested.

Remarks:

Stock Option

/s/Chase C. Leavitt, Attorney-

42,196

\$0.00

Common Stock

in-fact

11/14/2028

02/24/2023

42,196

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/21/2023

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

42,196